膽囊良、惡性病變組織中CA19-9 和CA125 的表達及其臨床病理意義_《中國普外基礎與臨床雜志》

作者：

劉潔瓊 , 楊竹林 , 苗雄鷹

中南大學湘雅二醫院肝膽胰疾病研究室( 長沙410011);

關鍵詞：

膽囊腺癌，慢性膽囊炎，腫瘤標志物

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　研究膽囊腺癌及其癌旁組織和慢性膽囊炎組織中CA1929 和CA125 表達水平并探討其臨床
病理意義。方法　108 例膽囊腺癌、46 例癌旁組織和35 例慢性膽囊炎手術切除標本常規石蠟包埋切片,應用En2
VisionTM免疫組化法檢測CA1929 和CA125 的蛋白表達。結果　膽囊腺癌組織中CA1929 和CA125 的表達陽性率
(49. 1 %、51. 9 %) 明顯高于癌旁組織(26. 1 %、15. 2 %) 和慢性膽囊炎組織(14. 3 %、5. 7 %) , P lt; 0. 01 。腺瘤癌變、
腫塊最大徑 lt; 2 cm、無淋巴結轉移和未侵犯周圍組織者CA1929 和CA125 的表達陽性率均明顯低于低分化腺癌、腫
塊最大徑≥2 cm、有淋巴結轉移和侵犯周圍組織器官者( P lt; 0. 05 , P lt; 0. 01) ; 兩者在膽囊腺癌中的表達具有一致性
(χ2 = 44. 69 , P lt; 0. 01) 。結論　CA1929 和CA125 可能是反映膽囊腺癌發生、發展、生物學行為和預后的重要腫瘤
標志物。

引用本文： 劉潔瓊,楊竹林,苗雄鷹. 膽囊良、惡性病變組織中CA19-9 和CA125 的表達及其臨床病理意義. 中國普外基礎與臨床雜志, 2008, 15(2): 92-95. doi: 復制

1.	<><><><><><><> [1]Passerini R,Riggio D,Salvatici M,et al.Interchangeability of measurements of CA19-9 in serum with four frequently used assays:an update[J].Clin Chem Lab Med,2007; 45(1):100.
2.	Locker GY,Hamilton S,Harris J,et al.ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J].J Clin Oncol,2006; 24(33):5313.
3.	Hogdall EV,Christensen L,Kjaer SK,et al.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish "MALOVA" Ovarian Cancer Study[J].Gynecol Oncol,2007; 104(3):508.
4.	王蘭君,李國興,王秀民.卵巢癌和胰腺癌患者血清CA125、CA19-9的水平相關分析[J].放射免疫學雜志,2007; 20(1):68.
5.	Plemenos MF,Dimas C,Kotsios A,et al.Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma[J].J BUON,2004; 9(1):73.
6.	Kushitani K,Takeshima Y,Amatya VJ,et al.Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma[J].Pathol Int,2007; 57(4):190.
7.	Rosen DG,Wang L,Atkinson JN,et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer[J].Gynecol Oncol,2005; 99(2):267.
8.	Tornos C,Soslow R,Chen S,et al.Expression of WT1,CA 125,and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary[J].Am J Surg Pathol,2005; 29(11):1482.
9.	Howell NR,Zheng W,Cheng L,et al.Carcinomas of ovary and lung with clear cell features:can immunohistochemistry help in differential diagnosis?[J].Int J Gynecol Pathol,2007; 26(2):134.
10.	吳泓,熊先澤,程南生,等.胰腺囊腺癌的診斷(附36例報告)[J].中國普外基礎與臨床雜志,2005; 12(5):509.
11.	楊風輝,宮東堯.外周血糖鏈抗原CA50及CA19-9在大腸癌中的應用價值[J].中國普外基礎與臨床雜志,2002; 9(2):封二.
12.	Grote T,Logsdon CD.Progress on molecular markers of pancreatic cancer[J].Curr Opin Gastroenterol,2007; 23(5):508.
13.	Nagao K,Itoh Y,Fujita K,et al.Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes[J].Int J Urol,2007; 14(9):795.
14.	Shukla VK,Gurubachan,Sharma D,et al.Diagnostic value of serum CA242,CA19-9,CA15-3 and CA125 in patients with carcinoma of the gallbladder[J].Trop Gastroenterol,2006; 27(4):160.
15.	Bouanène H,Harrabi I,Ferchichi S,et al.Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer[J].Bull Cancer,2007; 94(7):E18.
16.	Lipská L,Visokai V,Levy M,et al.Tumor markers in patients with relapse of colorectal carcinoma[J].Anticancer Res,2007; 27(4A):1901.
17.	Kang CM,Kim JY,Choi GH,et al.The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer[J].J Surg Res,2007; 140(1):31.
18.	Bast RC Jr,Feeney M,Lazarus H,et al.Reactivity of a monoclonal antibody with human ovarian carcinoma[J].J Clin Invest,1981; 68(5):1331.
19.	Liu PY,Alberts DS,Monk BJ,et al.An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy[J].J Clin Oncol,2007; 25(24):3615.
20.	Tsao KC,Hong JH,Wu TL,et al.Elevation of CA19-9 and chromogranin A,in addition to CA125,are detectable in benign tumors in leiomyomas and endometriosis[J].J Clin Lab Anal,2007; 21(3):193.

1. <><><><><><><> [1]Passerini R,Riggio D,Salvatici M,et al.Interchangeability of measurements of CA19-9 in serum with four frequently used assays:an update[J].Clin Chem Lab Med,2007; 45(1):100.
2. Locker GY,Hamilton S,Harris J,et al.ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer[J].J Clin Oncol,2006; 24(33):5313.
3. Hogdall EV,Christensen L,Kjaer SK,et al.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From The Danish "MALOVA" Ovarian Cancer Study[J].Gynecol Oncol,2007; 104(3):508.
4. 王蘭君,李國興,王秀民.卵巢癌和胰腺癌患者血清CA125、CA19-9的水平相關分析[J].放射免疫學雜志,2007; 20(1):68.
5. Plemenos MF,Dimas C,Kotsios A,et al.Prognostic significance of the immunohistochemical localization and serological detection of CA19-9 tumor antigen in colon carcinoma[J].J BUON,2004; 9(1):73.
6. Kushitani K,Takeshima Y,Amatya VJ,et al.Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma[J].Pathol Int,2007; 57(4):190.
7. Rosen DG,Wang L,Atkinson JN,et al.Potential markers that complement expression of CA125 in epithelial ovarian cancer[J].Gynecol Oncol,2005; 99(2):267.
8. Tornos C,Soslow R,Chen S,et al.Expression of WT1,CA 125,and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary[J].Am J Surg Pathol,2005; 29(11):1482.
9. Howell NR,Zheng W,Cheng L,et al.Carcinomas of ovary and lung with clear cell features:can immunohistochemistry help in differential diagnosis?[J].Int J Gynecol Pathol,2007; 26(2):134.
10. 吳泓,熊先澤,程南生,等.胰腺囊腺癌的診斷(附36例報告)[J].中國普外基礎與臨床雜志,2005; 12(5):509.
11. 楊風輝,宮東堯.外周血糖鏈抗原CA50及CA19-9在大腸癌中的應用價值[J].中國普外基礎與臨床雜志,2002; 9(2):封二.
12. Grote T,Logsdon CD.Progress on molecular markers of pancreatic cancer[J].Curr Opin Gastroenterol,2007; 23(5):508.
13. Nagao K,Itoh Y,Fujita K,et al.Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes[J].Int J Urol,2007; 14(9):795.
14. Shukla VK,Gurubachan,Sharma D,et al.Diagnostic value of serum CA242,CA19-9,CA15-3 and CA125 in patients with carcinoma of the gallbladder[J].Trop Gastroenterol,2006; 27(4):160.
15. Bouanène H,Harrabi I,Ferchichi S,et al.Factors predictive of elevated serum CA125 levels in patients with epithelial ovarian cancer[J].Bull Cancer,2007; 94(7):E18.
16. Lipská L,Visokai V,Levy M,et al.Tumor markers in patients with relapse of colorectal carcinoma[J].Anticancer Res,2007; 27(4A):1901.
17. Kang CM,Kim JY,Choi GH,et al.The use of adjusted preoperative CA19-9 to predict the recurrence of resectable pancreatic cancer[J].J Surg Res,2007; 140(1):31.
18. Bast RC Jr,Feeney M,Lazarus H,et al.Reactivity of a monoclonal antibody with human ovarian carcinoma[J].J Clin Invest,1981; 68(5):1331.
19. Liu PY,Alberts DS,Monk BJ,et al.An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy[J].J Clin Oncol,2007; 25(24):3615.
20. Tsao KC,Hong JH,Wu TL,et al.Elevation of CA19-9 and chromogranin A,in addition to CA125,are detectable in benign tumors in leiomyomas and endometriosis[J].J Clin Lab Anal,2007; 21(3):193.

《中國普外基礎與臨床雜志》

膽囊良、惡性病變組織中CA19-9 和CA125 的表達及其臨床病理意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

膽囊良、惡性病變組織中CA19-9 和CA125 的表達及其臨床病理意義

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料